Aurora Cannabis Inc.

NASDAQ:ACB

Drug Manufacturers - Specialty & Generic

Healthcare
$4.40 +0.51%

+$0.02 today

Market cap
$289.28M
Beta
1.34
P/E (TTM)
-3.2
EPS (TTM)
-$1.31
52W Low $2.73High $6.67

Volume 0.92M

Average 1.00M

ACB Income Before Tax

Profit after all operating and non-operating items but before income tax.

Aurora Cannabis Inc.NASDAQ: ACB

Income Before Tax · Q4 FY2026 · quarter ended Mar 2026

Income before tax turns positive

Q4 FY2026 income before tax was CA$11.44M, compared with -CA$19.99M a year earlier. Trailing-twelve-month income before tax was -CA$5.04M.

Context

  • Income before tax amounted to 17.6% of revenue in FY2026, up 11.7 pp from a year earlier.
  • Income before tax increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly income before tax holds near CA$11.44M or moves back toward the trailing-twelve-month quarterly average of -CA$1.26M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
CA$11.44M+824.7% QoQ
Last fiscal yearMar 2026
-CA$56.67M-378.0% YoY
LTMMar 2026
-CA$5.04M-124.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+157.2%——
1 year-378.0%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

CAD · from the income statement

Latest · FY2026
(56.67M) CAD
Year-over-year change
-378.0%

Income Before Tax vs competitors

How ACB compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -124.7% is the 8th highest of 10, against a peer median of +26.7%.
  • Income before tax amounts to 1.6% of revenue for ACB, versus a peer median of 44.2%.
ACB Competitors
Income Before Tax for ACB and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IRWDIronwood Pharmaceuticals, Inc.LTM Mar 2026$171.47M USD+615.4%-34.8%47.4%
ACBAurora Cannabis Inc.LTM Mar 2026-CA$5.04M CAD-124.7%—1.6%
LFMDLifeMD, Inc.LTM Mar 2026-$14.9M USD-64.3%—6.8%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$17.09M USD+26.7%—40.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$33.68M USD——24.9%
OGIOrganigram Global Inc.LTM Mar 2026-CA$38.89M CAD-329.7%—14.2%
HITIHigh Tide Inc.LTM Apr 2026-CA$45.98M CAD-416.6%—6.8%
ACRSAclaris Therapeutics, Inc.LTM Mar 2026-$69.66M USD+46.5%—832.6%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M USD-26.6%—871.8%
EDITEditas Medicine, Inc.LTM Mar 2026-$108.95M USD+56.6%—281.6%
CGCCanopy Growth CorporationLTM Mar 2026-CA$286.05M CAD+52.1%—91.6%
Peer median (excluding ACB) —+26.7%-34.8%44.2%

Competitors are the stored peer set for ACB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

CAD
Metric
FY2022
Jun 2022
FY2023
Mar 2023
FY2024
Mar 2024
FY2025
Mar 2025
FY2026
Mar 2026
Revenue221.34M223.8M270.28M343.29M321.42M
Cost of Revenue200.11M209.02M138.82M155.69M304.67M
Gross Profit21.23M14.78M131.46M187.61M16.75M
Gross Margin9.6%6.6%48.6%54.6%5.2%
Research & Development10.39M5.77M3.57M3.68M6.01M
Selling, General & Admin188.99M170.48M156.88M166.47M173.95M
Operating Expenses252.67M221.98M177.91M182.66M179.96M
Depreciation & Amortization93.66M52.59M33.07M22.55M14.23M
EBITDA(1.55B)(135M)(12.34M)51.35M(148.99M)
EBITDA Margin-702.4%-60.3%-4.6%15.0%-46.4%
Operating Income(231.45M)(207.19M)(46.45M)4.95M(163.21M)
Operating Margin-104.6%-92.6%-17.2%1.4%-50.8%
Interest Income4.51M19M12.81M11.51M5.86M
Interest Expense71.81M39.46M14.19M8.42M1.81M
Other Income / Expenses(1.49B)(576.51M)(13.15M)15.43M106.54M
Income Before Tax(1.72B)(783.7M)(59.6M)20.38M(56.67M)
Pre-Tax Margin-777.1%-350.2%-22.1%5.9%-17.6%
Income Tax Expense(2.14M)16.55M(554K)4.62M2.1M
Net Income(1.72B)(816.63M)(69.33M)1.59M(122.07M)
Net Margin-776.0%-364.9%-25.6%0.5%-38.0%
EPS (Basic)(79.92)(8.17)(1.28)0.03(2.15)
EPS (Diluted)(79.92)(8.17)(1.28)0.03(2.15)
Weighted Avg Shares21.49M32.27M51.26M54.88M56.71M
Weighted Avg Shares (Diluted)21.49M32.27M51.26M55.75M56.71M

Aurora Cannabis Inc.

NASDAQ:ACB

Intrinsic Alpha fair value

Locked

Current Price

$4.40

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.